Calico (company)
Search results
Apr 25, 2024 · We are at the forefront of developing a new class of therapeutics that may address the root cause of many diseases of aging. By selectively eliminating or modulating senescent cells, we may restore aging or damaged tissues to a more functionally healthy state. Learn More.
LEAD PRODUCT CANDIDATES. UNITY’s most advanced drug candidate, UBX1325, is currently being evaluated for the treatment of age-related diseases of the eye – including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival.
WE ASPIRE TO DEVELOP TRANSFORMATIVE MEDICINES TO SLOW, HALT, OR REVERSE DISEASES OF AGING. Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease.
Mar 15, 2022 · UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need.
THE SCIENCE. FROM MECHANISMS OF AGING TO POTENTIAL MEDICINES. Over the arc of life, our cells burn nutrients and oxygen for energy to fulfill specialized functions such as transmitting sensorial information, transporting blood, and defending us from cancer or invading organisms.
Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells.
Dec 12, 2023 · ASPIRE is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept in previously treated patients with active diabetic macular edema (DME) who are not achieving optimal benefit from standard of care.
Feb 6, 2024 · SOUTH SAN FRANCISCO, Calif. , April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2023
Jul 6, 2021 · SOUTH SAN FRANCISCO, Calif, July 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from DME or wet AMD for whom ...
Nov 1, 2022 · UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. In a Phase 1 clinical study in advanced wet AMD and DME, UBX1325 showed a favorable safety profile and improvements in visual acuity sustained through 24 weeks following a single intravitreal injection.
